

## Special Issue

# Cancer Metabolism and Resistance to Cell Death: Novel Therapeutic Perspectives 2nd Edition

### Message from the Guest Editor

Metabolic rewiring is a common feature of cancer cells which promotes tumorigenesis by sustaining uncontrolled proliferation, survival in an adverse microenvironment, invasion, metastasis and resistance to anticancer therapies. Cancer cells tightly control catabolic and anabolic reactions through a plethora of processes, including oncogenic activation, loss of tumor suppressors, genetic alterations in metabolic genes, epigenetic regulation and modulation by both microRNAs and long non-coding RNAs. The pivotal role of metabolic reprogramming in the resistance of cancer cells to different types of cell death, including apoptosis and ferroptosis, provides the rationale for anticancer strategies aimed at rewiring cancer cell metabolism. Such approaches have the potential to enhance the sensitivity of cancer cells to conventional and targeted therapies. This Special Issue of *Biomedicines* aims at dissecting the multifaceted connections between cancer metabolism and cell death pathways, with a focus on the pharmacological modulation of tumor metabolism as an anticancer strategy.

---

### Guest Editor

Dr. Francesco Ciccarese  
Istituto Oncologico Veneto IOV-IRCCS, via Gattamelata 64, 35128  
Padova, Italy

---

### Deadline for manuscript submissions

closed (30 June 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/194642](https://mdpi.com/si/194642)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).